Skip to main content
Premium Trial:

Request an Annual Quote

Jamey Marth to Direct New Nano Center at UC-Santa Barbara, Burnham

Premium

While there is no doubt that considerable headway has been made in the understanding of nucleic acids and proteins, two macromolecular components of the cell — lipids and glycans — are not so easily elucidated when it comes to their roles in disease. "They are not made by template-driven biological approaches, so you can't get at their structure or regulation by looking at the genome. ... I don't think there's any other way of doing it because I believe we're beginning to see the wall in biomedical research with a purely genomics/proteomics perspective," says Jamey Marth, director of the Center for Nanomedicine at the University of California, Santa Barbara. "So we have to use new technological approaches to integrate them and that's where nanotechnologies come in."

It was this belief in nanotechnology that made it a no-brainer for Marth, previously a professor of cellular and molecular medicine at the UC San Diego Medical Center, to accept the position of director of the new Center for Nanomedicine. The center will be launched and operated by both UCSB and the Burnham Institute for Medical Research. "I needed to make a big change in the orientation of my career in an environment that was at the envelope of nanotechnologies, and that's where Santa Barbara came in," says Marth, who joined the UCSB and Burnham Institute faculty in early July. "Their expertise in those fields synergize completely with the Burnham's abilities in biomedical research." Nanomedicine aims to utilize nanotechnology to develop drug delivery nanoparticles, biosensors, and other medical devices that function at the molecular scale for treating disease and repairing tissue.

The biggest challenge ahead for Marth and his team is not so much the development of nanoparticles, but learning how best to deliver them in the human body safely and effectively. "For the first time we're engineering devices that go into the body and we don't know a lot about them in many cases. … There are over 600 nanomaterials that are on the market right now, but that's just the tip of the iceberg," he says. "We need to understand more about them, their distribution, their fate, how to best use them. Different particles have different profiles in terms of their in vivo lifetimes and expectations of targeting or drug delivery."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.